StockNews.AI
ALNY
StockNews.AI
94 days

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B

1. Alnylam presents key results of vutrisiran Phase 3 study on ATTR-CM. 2. Study findings were showcased at a major European cardiology congress.

2m saved
Insight
Article

FAQ

Why Bullish?

Positive data from Phase 3 studies generally boost stock prices in biotech. Historical examples include successful trial results leading to significant upswings for similar biotech firms.

How important is it?

The presentation of Phase 3 trial results can catalyze investor interest and confidence. Given its impact on ALNY's primary product pipeline, this event is significant.

Why Short Term?

Initial reactions from clinical data presentations often affect stock prices quickly, evident during past biotech rallies post-conference.

Related Companies

AMGNSRPT
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of vutrisiran for the treatment of ATTR amyloidosis with cardiomyopathy (ATTR-CM) as a late-breaking abstract at the Heart Failure 2025 Congress, a scientific congress of the European Society of Cardiology, taking place May 17-20 in Belgrade, Serbia. The results demonstrate that vutrisiran, which rapi.

Related News